“…A key role for VEGF in tumour biology is supported by observations of production by numerous tumour cell lines (Senger et al, 1983(Senger et al, , 1986 and immunohistochemical demonstration in human carcinomas of several tissues, including breast Anan et al, 1996), lung (Mattern et al, 1996), liver , gastrointestinal tract (Brown et al, 1993b;Takahashi et al, 1995;Maeda et al, 1996), bladder (Brown et al, 1993a, O'Brien et al, 1995, kidney (Brown et al, 1993a;Sato et al, 1994;Takahashi et al, 1994) and ovary (Boocock et al, 1995; Abu-Jawdeh et al, (Toi et al, 1993;Guidi et al, 1994;Toi et al, 1994;Takahashi et al, 1995) and between VEGF expression and prognosis in breast, gastric and bladder cancer (O'Brien et al, 1995). Use of neutralizing antibodies to VEGF or transfection with antisense VEGF cDNA have been shown to result in inhibition of growth of tumour cell lines in nude mice and inhibition of metastatic spread (Asano et al, 1995;Warren et al, 1995;Claffey et al, 1996;Saleh et al, 1996).…”